SpaceX Eyes Nasdaq Listing as Starlink Drives Growth and Profitability Northland Capital Markets Raises PDF Solutions Price Target on Strong Quarterly Performance Global Stocks Gain as USIran Talks Show Progress Oil Prices Rise EU State Aid Surge Balancing China Competition and Single Market Unity Crude Oil Prices Remain Volatile Amid Middle East Tensions Julius Baer Suggests Crisis May Not Be Prolonged Pakistan Train Attack Raises Security Concerns May Weigh on Investor Sentiment FUL Q1 2026 Earnings EPS Slightly Beats Estimates as Stock Rises 25 SKLZ Q1 2026 Earnings EPS Miss of 109 Triggers 6 Stock Slide TDS Q1 2026 Earnings Massive EPS Surprise Fails to Lift Stock TCBK Q1 2026 Earnings EPS Surpasses Estimates by 527 Shares Edge Lower SLMBP Q1 2026 Earnings EPS Surges Past Estimates Preferred Stock Holds Steady SWBI Q1 2026 Earnings EPS Surprises Despite Flat Market Reception Estrella Immunopharma Inc ESLA Shows Modest Uptick Amid Sector Stability ITHAX Acquisition Corp III ITHA Holds Steady at 997 as Traders Eye Key Levels Alerus Financial ALRS Edges Higher as Stock Nears Resistance at 3034 Global Business Travel Group GBTG Holds Steady at 944 Amidst Consolidation Standex International SXI Edges Higher as It Tests Key Resistance Zone CFTC Takes Legal Action Against Rhode Island in Prediction Market Regulatory Dispute Processa Pharmaceuticals Inc PCSA Q4 2025 Earnings EPS Misses Estimates as Biotech Focuses on Clinical Pipeline Braskem BAK Slides 5 Petrochemical Gloom Weighs on ADR as Support Nears Ellington Residential Mortgage REIT Publishes Q4 2025 Earnings Transcript TAOP Q2 2011 Earnings EPS Misses Estimates but Stock Rallies 881 Pokmon Card Market Surges Nostalgia Speculation and HighProfile Collectors Fuel MultiMillion Dollar Sales OpenAI Reportedly Plans Confidential IPO Filing by May 22 Potential Valuation Up to 1 Trillion SpaceX IPO Opens to Retail Investors as Major Brokerages Democratize Access Knightscope Inc KSCP Q1 2026 Earnings WiderthanExpected Loss Amid Strategic Uncertainty BLTE Q4 2025 Earnings WiderthanExpected Loss as PreRevenue Biotech Remains Focused on Clinical Development